Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
about
Antigen-specific active immunotherapy for ovarian cancerAntigen-specific active immunotherapy for ovarian cancerImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerA randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma.Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory moleculesHumoral response to a viral glycan correlates with survival on PROSTVAC-VFCurrent status of mucins in the diagnosis and therapy of cancer.T cell coinhibition and immunotherapy in human breast cancerAnti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.Strategies for cancer vaccine development.Immunotherapy for metastatic solid cancersRecent advances in the development of breast cancer vaccines.Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.Immunotherapy for ovarian cancer: what's next?Reassessing target antigens for adoptive T-cell therapy.The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.Impact of tumour volume on the potential efficacy of therapeutic vaccines.Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cellsSipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics.Immunotherapy for ovarian cancer.Viral vector-based therapeutic cancer vaccinesA pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.Transmembrane mucins as novel therapeutic targetsTherapeutic vaccines for gastrointestinal cancers.Therapeutic cancer vaccines: current status and moving forward.Clinical evaluation of TRICOM vector therapeutic cancer vaccinesOverexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltrationPoxviral vectors for cancer immunotherapyA pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.Immunotherapy in ovarian cancer.Serum antibodies to blood group A predict survival on PROSTVAC-VF.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
P2860
Q24193567-9E10F74B-E71E-4543-959B-E3A4987172C5Q24240962-9451C8E6-1EF4-444A-8CDB-F57FC68588F6Q26996829-30D2F6EB-C350-4EEF-8DF9-4F4B197B6547Q33606083-5D8282BC-9D35-4D35-8E5D-76F17D9F219FQ33637231-ED44AEAA-DE80-43CC-A9CD-8D73C8F34BFAQ33674367-E9726E26-59FE-4F9E-A914-802A0157B03BQ33757326-0D17AD00-1189-435A-B6C3-31E5D69CBEB5Q33936154-076986F9-7910-4E0A-8E0D-A682B1FFF925Q34023497-97EA2BC3-D2D0-41E2-8600-3938F221C10FQ34038338-87E35B62-A98A-42E5-B1BB-E7128AE94F80Q34219970-132FE619-C4CE-416E-8D21-12F4C996D5DFQ34379303-934F8917-DFD5-41A6-BEEE-1A719254391AQ34431876-1323FA3D-8F25-4605-97B7-8D231D3E1A7AQ34494018-DDF24AB0-1EF6-46B8-B1AD-1DDE56295678Q34508125-7DF9E31B-0F4F-4DEC-AB10-697AD5F25CA4Q34743514-77127DC6-1147-437A-8E2A-8DFBAF348A07Q34789569-31F115DE-307F-4D34-A663-9961F766DEB3Q35000726-ABD3940C-21B1-483F-AD8E-042EBB465396Q35027034-499AA143-26E5-470F-9089-B4B5A866A74DQ35099116-59324C3B-3FE9-439F-B309-CB1CE301EC54Q35128716-CCECD704-1CFB-4F99-9C3B-4786BF4FF76CQ35155933-A4D0026D-FEAA-45BC-8517-CD85913E3DB2Q35164189-C1198C8D-7EC6-4B7C-B9B4-3878371D4364Q35515080-FBAC6603-B3E1-44BB-B11A-A19FCFC7692BQ35582228-174F45D6-BDA3-47C0-86DA-390AC80E4500Q35584269-F804838D-1B97-4F6D-9E6E-6E953DAE1C2FQ35591546-E3DB9314-3F81-44C2-8EDF-2D83A1E82DEEQ35632645-2926A22E-748D-4DBE-9B6A-25F5EEB74E5BQ35691248-99690715-2173-4BC1-9CD3-7D5D949828DDQ35894347-943A6477-77DA-4F63-81C2-A3BC6A3B48E2Q36099965-0CB46578-57D3-46BE-982D-6AC30F6A43D4Q36313292-FC76B742-7F55-411D-A6AA-D26A3E43C9FFQ36350388-89141802-D420-4267-A577-3B5357523EBDQ36444022-A680CA29-B785-41F5-A653-F497FA5206E9Q36508191-7FAB7789-8C7C-4E88-9C5A-9885B32057ECQ36544576-52C63A2A-CD18-4D05-BBBF-AB2C0C90E641Q36625406-4B43F33A-EDE5-43DF-8E9E-99F119DAD0D0Q36631249-DF64C084-9AAD-41EA-95F3-FED096D15FA9Q36674798-C750DD5C-7551-462E-9C18-E562185EBCF1Q36708792-A9F783CA-CC11-45A1-B453-D72C0210DB87
P2860
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pilot study of vaccination wit ...... ents with metastatic carcinoma
@en
Pilot study of vaccination wit ...... nts with metastatic carcinoma.
@nl
type
label
Pilot study of vaccination wit ...... ents with metastatic carcinoma
@en
Pilot study of vaccination wit ...... nts with metastatic carcinoma.
@nl
prefLabel
Pilot study of vaccination wit ...... ents with metastatic carcinoma
@en
Pilot study of vaccination wit ...... nts with metastatic carcinoma.
@nl
P2093
P2860
P1476
Pilot study of vaccination wit ...... ents with metastatic carcinoma
@en
P2093
Cinzia Remondo
Claudia Palena
Diane J Poole
Herbert Kotz
Jack P Higgins
Jacquin L Jones
James L Gulley
James W Hodge
Jeffrey Schlom
Junko Yokokawa
P2860
P304
P356
10.1158/1078-0432.CCR-08-0126
P407
P577
2008-05-01T00:00:00Z